{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.3","upperLimit":"88.5","value":"84.1"},{"groupId":"OG001","lowerLimit":"64.9","upperLimit":"77.6","value":"71.8"}]}],"title":"At 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.5","upperLimit":"78.9","value":"72.9"},{"groupId":"OG001","lowerLimit":"33.0","upperLimit":"50.9","value":"42.1"}]}],"title":"At 12 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"208"}],"units":"Participants"}],"description":"OS rate is calculated as the percentage of participants alive at the indicated timepoints","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks with placebo-matching dacarbazine solution administered IV every 3 weeks, until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion","id":"OG000","title":"Nivolumab, 3 mg/kg + Placebo-matching Dacarbazine"},{"description":"Participants received dacarbazine 1000 mg/m\\^2, solution administered IV every 3 weeks with placebo-matching nivolumab solution administered IV every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion","id":"OG001","title":"Dacarbazine, 1000 mg/m^2 + Placebo-matching Nivolumab"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to 6 months and or to 12 months","title":"Overall Survival (OS) Rate","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}